{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:46:06Z","timestamp":1791931566456,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004417","name":"Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a major public health challenge in Nepal, characterized by increasing drug-resistant TB (DR-TB) and constrained surveillance capacity. The sixth national DR-TB prevalence survey was therefore implemented to address this gap. This study aimed to estimate the national prevalence of DR-TB and identify risk factors among new and previously treated pulmonary TB patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A national cross-sectional survey was conducted from December 2022 to January 2024, enrolling bacteriologically confirmed pulmonary TB patients using stratified cluster sampling at 49 diagnostic centers. Phenotypic and genotypic drug sensitivity testing was performed on 1768\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      -confirmed samples. Logistic regression analysis estimated DR-TB prevalence and its associated risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Rifampicin resistance was identified in 2.2% [95% confidence interval (\n                      <jats:italic>CI<\/jats:italic>\n                      ) 1.4\u20133.6] of new TB patients and 10.1% (95%\n                      <jats:italic>CI<\/jats:italic>\n                      5.1\u201319) of previously treated patients. In total, 9.4% exhibited resistance to at least one first-line drug, with isoniazid exhibiting the highest resistance rate. Within the rifampicin-resistant TB (RR-TB) group, resistance to moxifloxacin was more prevalent among newly diagnosed patients than previously treated patients at both critical concentrations (55.3% vs. 33.3% at 0.25\u00a0\u00b5g\/ml; 34.2% vs. 11.1% at 1\u00a0\u00b5g\/ml). Previous TB treatment emerged as the strongest predictor of rifampicin resistance [adjusted odds ratio (a\n                      <jats:italic>OR<\/jats:italic>\n                      ) = 4.1, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      2.6\u20136.4].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of RR\/multidrug-resistant (MDR)-TB in Nepal remains stable compared with previous surveys. However, a high rate of fluoroquinolone resistance among new patients underscores the urgent need for improved antibiotic stewardship and expanded drug-susceptibility testing services. These findings provide essential evidence to guide national TB control strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40249-026-01503-z","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:39:31Z","timestamp":1791920371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-resistant tuberculosis in Nepal: the sixth national prevalence drug-resistant survey, 2024"],"prefix":"10.1186","volume":"15","author":[{"given":"Naveen Prakash","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuwan","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajowl","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasant Vikram","family":"Shahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lok Raj","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanav","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratna Bahadur","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Hada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuma","family":"Pun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Man","family":"Rajbhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwan","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabin","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barsha","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenza","family":"Bennani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bir Bahadur","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1503_CR1","volume-title":"Global tuberculosis report 2025","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization; 2025."},{"key":"1503_CR2","unstructured":"World Health Organization. Tuberculosis resurges as top infectious disease killer. https:\/\/www.who.int\/news\/item\/29-10-2024-tuberculosis-resurges-as-top-infectious-disease-killer. Accessed 22 Apr 2025."},{"key":"1503_CR3","volume-title":"Consolidated guidance on tuberculosis data generation and use: module 1. Tuberculosis surveillance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Consolidated guidance on tuberculosis data generation and use: module 1. Tuberculosis surveillance. Geneva: World Health Organization; 2024."},{"key":"1503_CR4","unstructured":"World Health Organization. Tuberculosis data. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data. Accessed 28 Mar 2025."},{"key":"1503_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3126\/saarctb.v16i2.23337","volume":"16","author":"SK Shrestha","year":"2018","unstructured":"Shrestha SK, Shah NP, Jha KK, Pant RP, Joshi LR, Bichha RP, et al. Challenges in the diagnosis of drug-resistant tuberculosis by GeneXpert MTB\/RIF in Nepal. SAARC J Tuberc Lung Dis HIV\/AIDS. 2018;16:8\u201315. https:\/\/doi.org\/10.3126\/saarctb.v16i2.23337.","journal-title":"SAARC J Tuberc Lung Dis HIV\/AIDS"},{"key":"1503_CR6","volume-title":"National guidelines on drug\u2011resistant tuberculosis management","author":"National Tuberculosis Control Center, Ministry of Health and Population, Nepal","year":"2023","unstructured":"National Tuberculosis Control Center, Ministry of Health and Population, Nepal. National guidelines on drug\u2011resistant tuberculosis management. Kathmandu: Ministry of Health and Population; 2023."},{"key":"1503_CR7","volume-title":"Guidelines for surveillance of drug resistance in tuberculosis","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 5th ed. Geneva: World Health Organization; 2015.","edition":"5th ed"},{"key":"1503_CR8","unstructured":"World Health Organization. GTB\u2011DRS GitHub repository. https:\/\/github.com\/GTB-DRS. Accessed 27 May 2025"},{"key":"1503_CR9","volume-title":"Annual health report 2080\/81","author":"Department of Health Services","year":"2024","unstructured":"Department of Health Services. Annual health report 2080\/81. Kathmandu: Government of Nepal; 2024."},{"key":"1503_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/S40249-024-01194-4","volume":"13","author":"A Parajuli","year":"2024","unstructured":"Parajuli A, Kakchapati S, Arjyal A, Joshi D, Kharel C, Otmani del Barrio M, et al. Assessing intersectional gender analysis in Nepal\u2019s health management information system: a case study on tuberculosis for inclusive health systems. Infect Dis Poverty. 2024;13:31. https:\/\/doi.org\/10.1186\/S40249-024-01194-4.","journal-title":"Infect Dis Poverty"},{"key":"1503_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002119","volume":"13","author":"KC Horton","year":"2016","unstructured":"Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex differences in tuberculosis burden and notifications in low\u2011 and middle\u2011income countries: a systematic review and meta\u2011analysis. PLoS Med. 2016;13:e1002119. https:\/\/doi.org\/10.1371\/journal.pmed.1002119.","journal-title":"PLoS Med"},{"key":"1503_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40249-023-01171-3","volume":"13","author":"W Muttamba","year":"2024","unstructured":"Muttamba W, Omongot S, Najjingo I, Nuwarinda R, Buregyeya E, del Barrio MO, et al. Using intersectional gender analysis to identify challenges in tuberculosis care at four health care facilities in Uganda. Infect Dis Poverty. 2024;13:2. https:\/\/doi.org\/10.1186\/s40249-023-01171-3.","journal-title":"Infect Dis Poverty"},{"key":"1503_CR13","volume-title":"Report of the first national anti-tuberculosis drug resistance survey","author":"Ministry of Health and Family Welfare, Government of India","year":"2016","unstructured":"Ministry of Health and Family Welfare, Government of India. Report of the first national anti-tuberculosis drug resistance survey. New Delhi: Ministry of Health and Family Welfare; 2016."},{"key":"1503_CR14","unstructured":"World Health Organization. Drug\u2011resistant TB. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2025\/tb-disease-burden\/1-3-drug-resistant-tb. Accessed 12 Apr 2026."},{"key":"1503_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5588\/IJTLD.14.0200","volume":"19","author":"SMM Kamal","year":"2015","unstructured":"Kamal SMM, Hossain MA, Sultana S, Begum V, Haque N, Ahmed MJ, et al. Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int J Tuberc Lung Dis. 2015;19:151\u20136. https:\/\/doi.org\/10.5588\/IJTLD.14.0200.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1503_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.5588\/IJTLD.10.0594","volume":"15","author":"B Buyankhishig","year":"2011","unstructured":"Buyankhishig B, Naranbat N, Mitarai S, Rieder HL. Nationwide survey of anti-tuberculosis drug resistance in Mongolia. Int J Tuberc Lung Dis. 2011;15:1201\u20135. https:\/\/doi.org\/10.5588\/IJTLD.10.0594.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1503_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.5588\/IJTLD.14.0785","volume":"19","author":"NV Nhung","year":"2015","unstructured":"Nhung NV, Hoa NB, Sy DN, Hennig CM, Dean AS. The fourth national anti\u2011tuberculosis drug resistance survey in Viet Nam. Int J Tuberc Lung Dis. 2015;19:670\u20135. https:\/\/doi.org\/10.5588\/IJTLD.14.0785.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1503_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/tmi.13502","volume":"26","author":"P Kamolwat","year":"2021","unstructured":"Kamolwat P, Nateniyom S, Chaiprasert A, Disratthakit A, Mahasirimongkol S, Yamada N, et al. Prevalence and associated risk factors of drug-resistant tuberculosis in Thailand: results from the fifth national anti-tuberculosis drug resistance survey. Trop Med Int Health. 2021;26:45\u201353. https:\/\/doi.org\/10.1111\/tmi.13502.","journal-title":"Trop Med Int Health"},{"key":"1503_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5588\/IJTLD.19.0186","volume":"24","author":"N Quispe","year":"2020","unstructured":"Quispe N, Asencios L, Obregon C, Velasquez GE, Mitnick CD, Lindeborg M, et al. The fourth national anti-tuberculosis drug resistance survey in Peru. Int J Tuberc Lung Dis. 2020;24:207. https:\/\/doi.org\/10.5588\/IJTLD.19.0186.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1503_CR20","doi-asserted-by":"publisher","first-page":"858","DOI":"10.5588\/IJTLD.18.0526","volume":"23","author":"N Ruswa","year":"2019","unstructured":"Ruswa N, Mavhunga F, Roscoe JC, Beukes A, Shipiki E, van Gorkom J, et al. Second nationwide anti\u2011tuberculosis drug resistance survey in Namibia. Int J Tuberc Lung Dis. 2019;23:858\u201364. https:\/\/doi.org\/10.5588\/IJTLD.18.0526.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1503_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070763","volume":"8","author":"D Lukoye","year":"2013","unstructured":"Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, et al. Anti\u2011tuberculosis drug resistance among new and previously treated sputum smear\u2011positive tuberculosis patients in Uganda: results of the first national survey. PLoS ONE. 2013;8:e70763. https:\/\/doi.org\/10.1371\/journal.pone.0070763.","journal-title":"PLoS ONE"},{"key":"1503_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/tmi.13205","volume":"24","author":"V Iem","year":"2019","unstructured":"Iem V, Dean A, Zignol M, Vongvichit P, Inthavong D, Siphanthong S, et al. Low prevalence of MDR\u2011TB in Lao PDR: results from the first national anti\u2011tuberculosis drug resistance survey. Trop Med Int Health. 2019;24:421\u201331. https:\/\/doi.org\/10.1111\/tmi.13205.","journal-title":"Trop Med Int Health"},{"key":"1503_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/tmi.13814","volume":"27","author":"BK Mutayoba","year":"2017","unstructured":"Mutayoba BK, Ershova J, Lyamuya E, Hoelscher M, Heinrich N, Kilale AM, et al. The second national anti\u2011tuberculosis drug resistance survey in Tanzania, 2017\u20132018. Trop Med Int Health. 2017;27:891\u2013901. https:\/\/doi.org\/10.1111\/tmi.13814.","journal-title":"Trop Med Int Health"},{"key":"1503_CR24","volume-title":"National tuberculosis management guidelines","author":"National Tuberculosis Control Center","year":"2019","unstructured":"National Tuberculosis Control Center. National tuberculosis management guidelines. Kathmandu: Ministry of Health and Population; 2019."},{"key":"1503_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.29245\/2689-9981\/2018\/2.1117","volume":"1","author":"G Mishra","year":"2018","unstructured":"Mishra G, Mulani J. First national anti-tuberculosis drug resistance survey (NDRS) from India: an eye opener. J Infectiol. 2018;1:26\u20139. https:\/\/doi.org\/10.29245\/2689-9981\/2018\/2.1117.","journal-title":"J Infectiol"},{"key":"1503_CR26","volume-title":"WHO treatment guidelines for isoniazid\u2011resistant tuberculosis","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. WHO treatment guidelines for isoniazid\u2011resistant tuberculosis. Geneva: World Health Organization; 2018."},{"key":"1503_CR27","doi-asserted-by":"publisher","first-page":"117863612311672","DOI":"10.1177\/11786361231167239","volume":"16","author":"K Ghimire","year":"2023","unstructured":"Ghimire K, Banjara MR, Marasini BP, Gyanwali P, Poudel S, Khatri E, et al. Antibiotics prescription, dispensing practices and antibiotic resistance pattern in common pathogens in Nepal: a narrative review. Microbiol Insights. 2023;16:117863612311672. https:\/\/doi.org\/10.1177\/11786361231167239.","journal-title":"Microbiol Insights"},{"key":"1503_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fmed.2019.00105","volume":"6","author":"KP Acharya","year":"2019","unstructured":"Acharya KP, Wilson RT. Antimicrobial resistance in Nepal. Front Med. 2019;6:105. https:\/\/doi.org\/10.3389\/fmed.2019.00105.","journal-title":"Front Med"},{"key":"1503_CR29","volume-title":"Global action plan on antimicrobial resistance","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2017."},{"key":"1503_CR30","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.5588\/PHA.14.0049","volume":"4","author":"N Alikhanova","year":"2014","unstructured":"Alikhanova N, Akhundova I, Seyfaddinova M, Mammadbayov E, Mirtskulava V, R\u00fcsch-Gerdes S, et al. First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis. Public Health Action. 2014;4:S17-23. https:\/\/doi.org\/10.5588\/PHA.14.0049.","journal-title":"Public Health Action"},{"key":"1503_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12879-023-08807-7","volume":"24","author":"W Amin","year":"2024","unstructured":"Amin W, Gadallah M, Salah A, Rady M. Prevalence of rifampicin-resistant tuberculosis among presumptive tuberculosis patients in Egypt, 2021: a national health facility-based survey. BMC Infect Dis. 2024;24:1\u20139. https:\/\/doi.org\/10.1186\/S12879-023-08807-7.","journal-title":"BMC Infect Dis"},{"key":"1503_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3126\/NPRCJMR.V2I12.87003","volume":"2","author":"A Rajbahak","year":"2025","unstructured":"Rajbahak A, Tamang A, Adhikari R. A decade in review: the evolving epidemiology of HIV and AIDS in Nepal. NPRC J Multidiscip Res. 2025;2:147\u201354. https:\/\/doi.org\/10.3126\/NPRCJMR.V2I12.87003.","journal-title":"NPRC J Multidiscip Res"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-026-01503-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-026-01503-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-026-01503-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:37Z","timestamp":1791928957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40249-026-01503-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1186\/s40249-026-01503-z","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was granted by the Nepal Health Research Council\n                      .\n                      Written informed consent was obtained from all participants. Confidentiality of the participants' information was maintained at every step, and results were disseminated to service providers in phases to facilitate appropriate management and referral.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"109"}}